Sun Pharma: Don’t Call Us, We’ll Call You On Biosimilars
Indian Firm Has Previously Been ‘Very Tentative’ Owing To Cost Of Projects
Speaking during its financial Q3 earnings call, Sun Pharma’s management has again pooh-poohed any idea of jumping into biosimilars in the near future, while providing updates on its trio of stricken Indian manufacturing facilities.
